Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2021.04.07
Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myelo ...
PDF (176 KB)
2021.04.06
DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Col ...
PDF (361 KB)
2021.03.29
DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Sma ...
PDF (298 KB)
2021.02.24
Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with ...
PDF (202 KB)
2021.02.22
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
PDF (131 KB)
2021.02.17
New Survey Reveals Nearly Half of Women Are Unfamiliar with a Condition that Affects Up to Five Mil ...
PDF (120 KB)
2021.02.03
HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with ...
PDF (180 KB)
2021.02.02
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research I ...
PDF (157 KB)
2021.01.29
Datopotamab Deruxtecan and ENHERTU® Show Promising Early Clinical Activity in Patients with Advance ...
PDF (326 KB)
2021.01.29
​​​​​​​New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutate ...
PDF (215 KB)
Showing 1 - 10 of 44 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...